EUVIMEDEUVIMED entdecken
Open Access

Relationship Between Anthracycline-cyclophosphamide Regimens and Docetaxel Monotherapy in Oral Mucositis Development

Yoshitaka Saito, Tatsuhiko Sakamoto, Yoh Takekuma, Masato Takahashi, Tomohiro Oshino, Mitsuru Sugawara

In Vivo · 2025

DOI: 10.21873/invivo.14021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Yoshitaka Saito und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan; saito-yo@hus…. Hauptthemen laut MEDLINE: Docetaxel, Stomatitis, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: We have previously reported that patients experiencing oral mucositis (OM) during anthracycline-cyclophosphamide treatment develop symptoms following subsequent docetaxel-containing chemotherapy for perioperative breast cancer therapy. However, the concomitant use of pertuzumab and trastuzumab with docetaxel has also been suggested as a significant risk factor for OM. This study aimed to further evaluate the direct relationship of OM with anthracycline-cyclophosphamide treatment and docetaxel monotherapy. PATIENTS AND METHODS: Patients with breast cancer who underwent anthracycline-cyclophosphamide treatment followed by docetaxel monotherapy as perioperative therapy (n=63) were divided into control and OM-experience groups based on the absence or presence of OM development during prior anthracycline-cyclophosphamide treatment, and retrospectively evaluated. The primary endpoint was the comparison of all-grade OM incidence in the first docetaxel cycle between the two groups. The incidence of OM and dysgeusia was also assessed across all treatment cycles. RESULTS: The incidence of all-grade OM was 42.9% in the OM-experience group and 9.5% in the control group during the first cycle (p=0.006) and 47.6% and 11.9% across all treatment cycles (p=0.004), thereby achieving the primary endpoint. In contrast, the incidence of grade ≥2 OM in both settings was higher in the OM-experience group than in the control group, although the difference was not statistically significant (14.3% vs. 2.4%, p=0.10 for both settings). Moreover, the incidence of dysgeusia did not differ between the two groups. CONCLUSION: Patients exhibiting OM during prior anthracycline-cyclophosphamide treatment were significantly more likely to develop symptoms during subsequent docetaxel monotherapy for perioperative breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelStomatitisAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsHumansFemaleCyclophosphamideMiddle AgedAnthracyclinesAdultRetrospective StudiesAgedIncidence

Stichwörter der Autor:innen

Oral mucositisanthracyclinecyclophosphamidedocetaxeldysgeusia

Substanzen

DocetaxelCyclophosphamideAnthracyclines

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan; saito-yo@hus.ac.jp.
  • Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan.
  • Department of Breast Surgery, Hokkaido University Hospital, Sapporo, Japan.
  • Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Zitieren

APA

Saito, Y., Sakamoto, T., Takekuma, Y., Takahashi, M., Oshino, T., & Sugawara, M. (2025). Relationship Between Anthracycline-cyclophosphamide Regimens and Docetaxel Monotherapy in Oral Mucositis Development. In Vivo. https://doi.org/10.21873/invivo.14021

Vancouver

Saito Y, Sakamoto T, Takekuma Y, Takahashi M, Oshino T, Sugawara M. Relationship Between Anthracycline-cyclophosphamide Regimens and Docetaxel Monotherapy in Oral Mucositis Development. In Vivo. 2025. doi:10.21873/invivo.14021

BibTeX
@article{Saito2025,
  author = {Saito, Yoshitaka and Sakamoto, Tatsuhiko and Takekuma, Yoh and Takahashi, Masato and Oshino, Tomohiro and Sugawara, Mitsuru},
  title = {Relationship Between Anthracycline-cyclophosphamide Regimens and Docetaxel Monotherapy in Oral Mucositis Development},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.14021}
}
Kostenlos starten →